Connect with us

Technology

ESMO 2024: Stay Informed with Real-Time Coverage and Analysis from DelveInsight

Published

on

As the stage is set for another year of groundbreaking research and transformative treatment advancements, several companies are seizing the opportunity to present their data readouts. DelveInsight’s oncology consultants and analysts will be closely tracking the key oncology abstracts and datasets to watch at ESMO 2024.

LAS VEGAS, Sept. 13, 2024 /PRNewswire/ — The ESMO conference is a key event in the field of oncology, serving as a vital platform for sharing the latest breakthroughs in cancer research and treatment. Held annually, this conference provides a thorough overview of the most recent advancements across various oncology sub-specialties.

As the ESMO 2024 annual meeting approaches, numerous pharmaceutical companies are preparing to present their latest data. DelveInsight invites you to discover the newest developments in oncology research and development.

The DelveInsight team is ready to provide exceptional coverage, engaging with experts and professionals across the oncology field. We will participate in oral abstract presentations, interactive workshops, and poster and educational sessions, all tailored to the specific interests of clinical oncologists and researchers.

Stay tuned with DelveInsight’s analysis of key themes and results at our page: ESMO 2024 Conference

We prioritize industry-sponsored and highly anticipated trial data presentations. Experience the buzz at ESMO 2024 as we analyze key sessions and unveil the latest advancements shaping the future of oncology.

DelveInsight’s ESMO Conference Coverage Solutions will help the client in several ways:

Get data-driven insights generated through interpretation of Key Oral Abstracts presentations inclusive of all relevant Session Types such as Mini Oral, Industry Satellite Symposium, Proffered paper session, Educational Sessions, and EONS sessions.Insights driven through interaction with Presentors/Oncologists/Researchers on industry-affiliated Poster sessions.The agenda is to cover all pivotal trials, Late Breaking Abstracts (LBAs), efficacy data of first-in-class therapies targeting novel mutations, along with key company collaborations taking place on-site.Provide a pre-conference program to showcase the range of topics covered in each indication.Prioritizing abstracts highlighting the most pressing patient needs in terms of cancer screening (MRD testing and Early cancer detections), early-stage cancer treatment, and mutation/protein detection for making accurate therapy decisions for relapsed/refractory patients.Connecting with Keynote speakers to understand geographical variations and challenges in terms of cancer screening and treatment recommendations, thereby understanding the differences in clinical practices within a small community of physicians.Offer valuable information regarding upcoming biomarkers, potential applications, and market segments, while analyzing current trends in the utilization of biomarkers for both prevention and diagnosis.In-depth examinations of the latest updates from clinical trials and advancements in treatment approaches, coupled with shifts in treatment strategies resulting from the latest data and changes in conventional practices.In addition to coverage of key abstracts of potential therapy areas (Lung Cancer, Breast Cancer, Genitourinary Cancer, Gastrointestinal Cancer, Gynecologic Cancer, and Hematological Malignancies), tracking the latest advancements by diagnostic companies focussing on screening and surveillance through tumor/tissue and liquid biopsy.Keep a close watch and synthesize the information regarding the most recent successes and failures in potential fields.

Connect with our Oncology Subject Matter expert to understand how to leverage ESMO Conference Solutions for maximum benefit

Oncology Conference Coverage Services: DelveInsight’s Oncology Conference Coverage Services offer a thorough analysis of outcomes from major events like ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, the European CAR T-cell Meeting, and IASLC. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies.

Oncology Portfolio Management: DelveInsight’s deep expertise in oncology distinguishes us, as we excel in understanding the complexities of the cancer field. Our core focus is on aligning with strategic goals, analyzing advancements in the oncology sector, assessing the current demands of the oncology market, and providing exceptional client services.

Rare Diseases Analysis: At DelveInsight, we are dedicated to providing essential reports that address the complexities of the rare cancer market. Our team of expert analysts diligently tracks the evolving developmental, regulatory, and commercial environments of competing products. We offer a range of services, including insightful conference evaluations and in-depth analyses of company progress and R&D activities, all designed to support the smooth development of oncology solutions tailored to our clients’ specific requirements.

Oncology Pipeline Assessment: Our oncology pipeline evaluation offers a comprehensive overview of cancer treatment options, clinical trials, and key areas within the cancer therapeutics field, all summarized in an accessible report format. The oncology-focused reports, available in our Report Store, provide in-depth insights into treatment strategies, mechanisms of action (MoAs), drug components, and launch plans for therapies in the late stages of development. This assessment enhances understanding of their launch timelines and strategic initiatives.

R&D Analysis: Our skilled research and development analyst specializes in the complexities of oncology, offering essential insights and advice to clients aiming to advance in oncological research and development. They utilize a methodical assessment approach, aligned with industry norms, to track the progress of each oncology drug in both pre-clinical and clinical stages. DelveInsight’s comprehensive oncological reports are crafted to reduce uncertainties and highlight overlooked areas, providing organizations with timely and strategic intelligence.

Stay tuned with DelveInsight’s team for all the latest updates and breakthroughs happening at ESMO 2024 and how the results are going to impact the treatment paradigm along with an analysis of the overall impact on the indication market landscape.

Get an exclusive glimpse of ESMO 2024 Annual Meeting Preview Content

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/esmo-2024-stay-informed-with-real-time-coverage-and-analysis-from-delveinsight-302247541.html

SOURCE DelveInsight Business Research, LLP

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Siyata Mobile Products Deployed by EMS Organization in Papua New Guinea

Published

on

By

VANCOUVER, BC, Nov. 13, 2024 /CNW/ — Siyata Mobile Inc. (Nasdaq: SYTA) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (“PoC”) devices and cellular signal booster systems, today discussed the deployment of its SD7 handsets and VK7 vehicle kits by The National St John Ambulance Service (NStJA), a trusted life-saving service in Papua New Guinea, the most populous Pacific island country.

Marc Seelenfreund, CEO of Siyata, commented, “By upgrading from standard smartphones to our ruggedized SD7 handsets and VK7 vehicle kits, NStJA is experiencing the many benefits of our solution. Our devices stand up to the demanding environments faced by first responders and medical personnel. Integrated with the Zello Push-to-Talk app, our solution for this customer is providing secure and reliable communication that far exceeds the performance of standard smartphones. Our global deployments continue to increase, and we are pleased that our reach now extends to Papua New Guinea, and we are also encouraged by the number of new customers who are selecting Zello as their preferred PTT application.” 

Mark Cannon, Chief Executive for NStJA, commented, “We provide mission-critical evacuation and medical services to residents and visitors of our country. It is absolutely critical that we have a communications solution that is reliable and effective. Since upgrading from standard smartphones and a traditional UHF radio system, our team is finding the Siyata devices to be simpler to use with a PTT button, provide loud and clear audio and have a better battery life. We are quite pleased with Siyata’s solution.”

About Siyata Mobile

Siyata Mobile Inc. is a B2B global developer and vendor of next-generation Push-To-Talk over Cellular handsets and accessories. Its portfolio of rugged PTT handsets and accessories enables first responders and enterprise workers to instantly communicate over a nationwide cellular network of choice, to increase situational awareness and save lives. Police, fire, and ambulance organizations as well as schools, utilities, security companies, hospitals, waste management companies, resorts and many other organizations use Siyata PTT handsets and accessories today.

In support of our Push-to-Talk handsets and accessories, Siyata also offers enterprise-grade In-Vehicle solutions and Cellular Booster systems enabling our customers to communicate effectively when they are in their vehicles, and even in areas where the cellular signal is weak.

Siyata sells its portfolio through leading North American cellular carriers, and through international cellular carriers and distributors.

Siyata’s common shares trade on the Nasdaq under the symbol “SYTA”, and its warrants trade under the symbol “SYTAW”.

Visit www.siyata.net and unidencellular.com to learn more.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Siyata’s current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of Siyata could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Siyata’s filings with the Securities and Exchange Commission (“SEC”), and in any subsequent filings with the SEC. Except as otherwise required by law, Siyata undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites and social media have been provided as a convenience, and the information contained on such websites or social media is not incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/siyata-mobile-products-deployed-by-ems-organization-in-papua-new-guinea-302303831.html

SOURCE Siyata Mobile Inc.

Continue Reading

Technology

Forsea Achieves Record-Breaking Cell Density for Its Cultivated Seafood

Published

on

By

Forsea’s technology sets new industry standard, paving the way for affordable cultivated seafood production.

REHOVOT, Israel, Nov. 13, 2024 /PRNewswire/ — Cell-cultivated seafood innovator Forsea struck a major breakthrough in making freshwater eel farming a viable commercial reality. The start-up announced its organoid technology reached a record-breaking cell density of more than 300 million cells/ml, and with minimal and precise use of cultured media ingredients.

This is the highest cell density recorded in the field, moving Forsea to the forefront of cultured seafood production efficiency. The landmark technology allows for a scalable and highly cost-effective supply for the hugely popular traditional Japanese delicacy, eel (unagi) whose availability has been significantly hampered by overfishing and the destruction of aquatic ecosystems.

Eel is Big in Japan

Forsea is currently focusing on manufacturing cultured freshwater eel due to the immense market potential, particularly in Japan. As the world’s largest consumer of eel, Japan recorded sales of 140,000 tons in 2023—50% of total global sales. The traditional Japanese dish unagi (eel) is considered a premium delicacy, prized not only for its rich flavor and tender texture but also because of its rarity. Freshwater eel is endangered and cannot be commercially bred in captivity. Demand for eel far surpasses the industry’s current supply capabilities, translating to skyrocketing prices.

Better, faster, and economical

Setting a new standard for “blue ocean” initiatives, Forsea created a new approach to cell cultivating fish tissues outside of their native water habitats via organoid technology. Forsea’s patent-protected platform involves creating the ideal environment for animal cells to spontaneously assemble into three-dimensional tissue structures with their natural composition of fat, muscle and connective tissue.

This method not only echoes the natural growth process of these tissues in a living animal, giving it a closer-to-nature edge, it bypasses the scaffolding stage and is dramatically less dependent on expensive growth factors. This makes the process highly affordable and positions its cell-grown version to price parity (or potentially lower)  with traditional aquafarmed eel, a key challenge the cell-based industry was desperate to overcome.

Ample affordable cultivated eel not oceans away

“The breakthrough to this level of cell density highlights the strength of our organoid technology,” exclaims Moria Shimoni, CTO of Forsea. “It’s a validation of our approach to high-efficiency cultivation of seafood to meet both economic and sustainability goals at scale”.

After completing its proof-of-concept continuous harvesting process, Forsea reports it is ready to take production of its cultured fish products to the next phase of commercial scale-up.

“Forsea’s organoid technology requires less capital expenditure than other technologies,” explains Roee Nir, Founder and CEO of Forsea. “Achieving this level of cell density with minimal resources will translate to substantial reductions in the unit of economics and will bring cultured seafood production to a cost that is actually below the traditional market price. This is major milestone for Forsea and validates our vision of making sustainable, high-quality seafood affordable and widely accessible. It also sets a powerful precedent for scaling other cultured seafood products and establishing sustainable alternative supply chains for ecologically sensitive species.”

Forsea’s cell-cultured eel is expected to ease the strain on the world’s eel populations and reduce environmental impact of traditional eel farming. This encompasses reducing global warming potential, water consumption, and land use and alleviated pressure on marine ecosystems by focusing on endangered species.

“Our recent industry survey shows that cultivated meat production is definitely not a one-size-fits-all approach,” says Elliot Swartz, Principal Scientist Cultivated Meat, GFI. “It’s encouraging to see positive data from companies showing how different methods can address challenges in cost and scale. I’m especially pleased to see a GFI research grantee, Dr. Iftach Nachman, help a startup pioneer new ways of cultivating meat. This is a great example of how foundational open-access science enables and makes possible follow-on work by the private sector.”   

The company is preparing for commercial launch of its unagi product in 2026. Earlier this year, Forsea held a successful tasing event at the reputable ‘a’ restaurant in Tel Aviv, where it served the world’s first cultivated unagi kabayaki—grilled fresh eel on a bed of aromatic rice—receiving rave reviews. Among the tasters where representatives from the Japanese embassy and various Japanese food companies based in Israel.

About Forsea
Forsea was founded by biotech engineer Roee Nir, MBA; Moria Shimoni, PhD; Iftach Nachman, PhD; and Yaniv Elkouby, PhD with support from the Israeli Innovation Authority (IIA) and The Kitchen Hub. It has garnered seed backing from Target Global, PeakBridge VC, Future Food Fund, Zora Ventures, FoodHack, and M&H Ventures. Forsea’s organoid approach to cultivating fish tissue involves creating an ideal environment for fish cells to spontaneously form their natural composition of native fat and muscle. They grow as a three-dimensional tissue structure, just as in nature.

For more information, contact:

Company Contact

Forsea Foods Ltd.

Roee Nir, CEO and Co-Founder

Email: info@forseafoods.com

Web:   www.forseafoods.com 

Press Contact

NutriPR

Liat Simha

Tel: +972-9-9742893

E-mail: liat@nutripr.com

Web: www.nutripr.com

 

Photo: https://mma.prnewswire.com/media/2555423/Forsea_Foods.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/forsea-achieves-record-breaking-cell-density-for-its-cultivated-seafood-302304008.html

SOURCE Forsea Foods

Continue Reading

Technology

EP3® Technology Powers $560 Million in U.S. Election Contracts: The Invisible Engine Behind ForecastEx’s Fast-Growing Predictions Market

Published

on

By

AUSTIN, Texas, Nov. 13, 2024 /PRNewswire/ — ForecastEx, a wholly-owned subsidiary of Interactive Brokers (IBKR) and a US-regulated predictions exchange and clearinghouse, processed an impressive $560 million+ in election contracts for the 2024 U.S. general election. The innovative technology driving those contracts? Connamara Technologies’ EP3 ® matching engine and exchange platform.

The election showed EP3’s resilience and commitment to seamless, high-volume processing for predictive events.

In the days leading up to – and during – election night, EP3 operated like the gears of a fine timepiece: inconspicuous, vital, and unfaltering. This synchronicity of unyielding performance weathered waves of volatility and seamlessly processed trades at a record volume.

Working in concert with ForecastEx’s internal teams, Connamara Technologies’ engineers monitored systems around the clock, ready to respond to surges in trade volume with precision and expertise. The team’s commitment went beyond standard duty, ensuring unparalleled service during this first-in-a-lifetime historic trading event.

With EP3 powering its trading, ForecastEx has not only established a benchmark for transparency in elections but has also offered the public real-time, market-based insights into election sentiment. EP3 operates from a legacy of trading knowledge that dates back to the late 1980s.

“While you may not recognize the name EP3 just yet, you’ll certainly recognize our impact. Whether you placed a trade or watched from afar, the 2024 election proved our technology’s resilience and our team’s commitment to deliver seamless, high-volume processing at every turn for future predictive events,” said Jim Downs, Co-Founder and CEO of Connamara Technologies.

As predictions markets continue to grow, the unseen elements – the EP3 technology and the engineers who support it – will remain crucial to providing reliable, transparent platforms that allow for public sentiment to be expressed and analyzed in real-time. Moving forward, Connamara Technologies aims to expand EP3’s reach, enabling new exchanges and markets to take advantage of this dependable backbone technology.

About Connamara Technologies

Connamara Technologies is the leading provider of fully-integrated exchange infrastructure, empowering new and existing exchanges to operate with exceptional efficiency and reliability. Its EP3 platform is a new breed of exchange and clearing technology that seamlessly integrates all key functions into a single, robust platform. It is cost-accessible, adaptable, scalable and quick-to-market. Engineered for the evolving needs of the next generation of exchanges and marketplaces, EP3 is shaping the future of financial markets.

For more, visit www.connamara.tech or LinkedIn.

Media Contact:

Claire Downs
marketing@connamara.tech

View original content:https://www.prnewswire.com/news-releases/ep3-technology-powers-560-million-in-us-election-contracts-the-invisible-engine-behind-forecastexs-fast-growing-predictions-market-302303513.html

SOURCE Connamara Technologies

Continue Reading

Trending